ライフサイエンスコーパス: immunization schedule

1 V13) was introduced to the routine childhood immunization schedule.

2 ecently incorporated into the United Kingdom immunization schedule.

3 ate vaccine (MCCV) into their routine infant immunization schedule.

4 h titers increasing progressively during the immunization schedule.

5 s PCV7 was being introduced into the routine immunization schedule.

6 FP-specific humoral responses using the same immunization schedule.

7 al fractional-dose IPV (fIPV) in its routine immunization schedule.

8 vaccine on the United Kingdom's 2/3/4-month immunization schedule.

9 ivery by using a parenteral prime-oral boost immunization schedule.

10 al conjugate vaccines (PCVs) into the infant immunization schedule.

11 unced in children, we recommend adapting the immunization schedule.

12 Africa prior to introduction of RCVs in the immunization schedule.

13 es are an expensive component of the routine immunization schedule.

14 ltiple-injection visits included in national immunization schedules.

15 cines included in the 2010 annual harmonized immunization schedules.

16 de introduction of RCV in national childhood immunization schedules.

17 ldhood when incorporated into routine infant immunization schedules.

18 otein B (CMV gB)/MF59 vaccine at 3 different immunization schedules.

19 o rubella-containing vaccines (RCV) in their immunization schedules.

20 alent IPV or combined vaccines for childhood immunization schedules.

21 g 2013-2015, 85 countries added IPV to their immunization schedules, 46 (55%) of which adopted a sche

22 mpliance with the recommended 2-dose measles immunization schedule, 6% of high school students were s

23 roduced into the country's routine childhood immunization schedule after the campaign.

24 l trial (RCT), called ICI-VPH (Impact of HPV Immunization Schedules Against HPV), was conducted in Qu

25 transmission together with completion of the immunization schedule also to reduce the perinatal risk

26 Recent changes in the routine immunization schedule and a renewed emphasis on vaccine

27 ess the immunogenicity of the new bOPV + IPV immunization schedule and gains in type 2 immunity with

28 + inactivated poliovirus vaccine (bOPV+IPV) immunization schedule and gains in type 2 immunity with

29 e Country, where neonatal BCG is part of the immunization schedule and has a 100% coverage) as compar

30 rapidly introduced into the Alaska childhood immunization schedule and reduced colonization by PCV6+

31 relevant stakeholders when planning routine immunization schedules and supplemental immunization act

32 e of vaccine, but we evaluated two different immunization schedules and the oropharyngeal and intrana

33 rning neonatal herpes infections, poliovirus immunization schedule, and group B streptococcus screeni

34 of influenza illness seasonality, influenza immunization schedules, and gestation itself.

35 inactivated poliovirus vaccine into routine immunization schedules, and it describes the proposed im

36 hat did not yet include it in their national immunization schedules, and to "switch" from trivalent O

37 Active immunization schedules are being developed to minimize T

38 er vaccines within the Expanded Programme on Immunization schedule at 9 months.

39 2017 into the routine Expanded Programme for Immunization schedule at age 15-18 months, concomitantly

40 ing a single IPV dose to an OPV-only routine immunization schedule at or just before OPV cessation pr

41 bias may become more likely in the future as immunization schedules become more complex and variable.

42 An accelerated immunization schedule (birth, 2 weeks, 2 months, and 5 m

43 Inactivated Polio Vaccine (IPV) into routine immunization schedules by the end of 2015.

44 vated polio vaccine (IPV) into their routine immunization schedules by the end of 2015.

45 pandemic caused major disruptions to normal immunization schedules, causing the omission or delay of

46 table vaccines delivered through the routine immunization schedule: diphtheria-tetanus-pertussis vacc

47 ng of maternal protection and routine infant immunization schedules, exacerbated by the failure of va

48 f varicella vaccine was added to the routine immunization schedule for children in June 2006 by the C

49 care professionals may not conform to proper immunization schedules for premature and low-birth-weigh

50 orthcoming withdrawal of OPV from the infant immunization schedule globally has the potential to impr

51 cts received placebo, 13 received a complete immunization schedule (> or = 3 injections), and 6 were

52 (RRV-TV), which was incorporated into the US immunization schedule in 1998.

53 ugate vaccine (PCV7) into the U.S. childhood immunization schedule in 2000 has substantially reduced

54 ne 2 was globally withdrawn from the routine immunization schedule in 2016, soon after the certificat

55 Introduction of PCV7 into the routine infant immunization schedule in a community with a high prevale

56 t rotavirus vaccine (RV1) into its childhood immunization schedule in April 2012.

57 IPV) after its introduction into the routine immunization schedule in Bangladesh.

58 ugate vaccine (PCV7) into the routine infant immunization schedule in England, Wales, and Northern Ir

59 vaccination was introduced into the routine immunization schedule in the United States in late 2006

60 nce of the HPV vaccination from the national immunization schedule in three participating countries (

61 ion of at least one dose of IPV into routine immunization schedules in 126 all OPV-using countries by

62 The use of 4 different PCV13 immunization schedules in healthy term infants resulted

63 ebec, Canada, where a routine 2-dose measles immunization schedule, in which measles vaccine is given

64 The revised childhood immunization schedule included 2 doses of IPV at 2 and 4

65 The Burkina Faso immunization schedule includes yellow fever vaccine (YFV

66 Any changes to the infant PCV13 immunization schedule may disproportionally affect prema

67 The same immunization schedule, MVA dose, and challenge condition

68 With an immunization schedule of 3 sets of 3 weekly injections,

69 Many adult immunization schedules recommend that tetanus and diphth

70 The design of infant immunization schedules requires an understanding of the

71 mumps-rubella-varicella (MMRV) vaccine, into immunization schedules should be evaluated from a benefi

72 is B vaccine has been included in the infant immunization schedule since 1991 in the United States.

73 ntaining vaccines in their routine childhood immunization schedules, supported through the Expanded P

74 cine and subsequent switch to their national immunization schedules.The purpose of this article is to

75 lowing PCV13 introduction into the Cambodian immunization schedule, there have been declines in VT pn

76 As countries transition to IPV in immunization schedules, they may need to actively manage

77 present two-dose measles-mumps-rubella (MMR) immunization schedule to one-dose of MMR; second, the us

78 assays provide an opportunity to study other immunization schedules to gain a broader understanding o

79 how a greater differential response to the 2 immunization schedules used in this study suggests that

80 e regimen, in which the standard 0-1-2 month immunization schedule was modified to a 0-1-7 month sche

81 aRT plus IFN-gamma and IFN-gamma alone), the immunization schedule was reduced to 0, 4, and 8 weeks.

82 included in the current Expanded Program on Immunization schedule, we estimated the reduction in rot

83 tion of the varicella vaccine to the routine immunization schedule, we have observed a 70% reduction

84 r optimization in vaccine composition and/or immunization schedule will be required to induce longer-

85 a median of 30 days after completion of the immunization schedule with either mRNA vaccine or a sing

86 future control of B. pertussis will require immunization schedules with new acellular vaccines that

87 Immunization schedules with pneumococcal conjugate vacci